The FDA informed Intercept that it is unable to approve the sNDA in its current form, consistent with the outcome of the Gastrointestinal Drugs Advisory Committee (GIDAC) meeting in September 2024. In ...

After a person quits smoking, an important consideration is how quickly the induction of CYP1A2 dissipates. The primary pharmacokinetic interactions with smoking occur with drugs that are CYP1A2 ...

The proposed mechanism by which the fluoroquinolones induce glycemic abnormalities is not clearly understood. Reports of fluoroquinolone-induced hypoglycemia are abundant, but reports of ...